Quote:I have this same question, if 88 percent end up with PD-L1 inhibitors that strip away defenses, would there be a reason why the other 12 percent don't and could that be equally important in beating the cancer?
There are genetic mutations that keep PD-L1 levels very low. There's also the possibility of a highly compromised immune system where leronlimab would not increase M1 macrophages and you wouldn't get a corresponding rise in PD-L1.